Table 2.
Cycle outcomes compared before and during coronavirus disease 2019.
| Cycle characteristics and outcomes | Before COVID-19 (6/17/19 to 2/28/20) | During COVID-19 (6/17/20 to 2/28/21) | P value |
|---|---|---|---|
| COS cycles initiated (n) | 1,352 | 1,693 | .02 |
| Retrieval performed | 1,241 (92%) | 1,591 (94%) | |
| Cycle canceled | 111 (8%) | 102 (6%) | |
| Reason for cancelation | .01 | ||
| Low response | 98 (88%) | 74 (73%) | |
| Premature ovulation | 8 (7%) | 14 (14%) | |
| Positive COVID-19 PCR | 6 (6%) | ||
| Other | 5 (5%) | 8 (8%) | |
| Cycle type | .19 | ||
| In vitro fertilization | 858 (63%) | 1,142 (67%) | |
| Elective oocyte cryopreservation | 347 (26%) | 383 (23%) | |
| Elective embryo banking | 62 (5%) | 70 (4%) | |
| Medical oocyte cryopreservation | 29 (2%) | 42 (2%) | |
| Medical embryo banking | 23 (2%) | 27 (2%) | |
| Oocyte donation | 33 (2%) | 29 (2%) | |
| Cycle characteristics | |||
| Total gonadotropins, median | 3,925 IU | 3,900 IU | .49 |
| Day 2 FSH,c median | 6.1 mIU/mL | 7.4 mIU/mL | <.01 |
| Day 2 estradiol,c median | 56 pg/mL | 41 pg/mL | <.01 |
| Estradiol on trigger day,c median | 2,421 pg/mL | 2,626 pg/mL | .01 |
| Cycle outcomes | |||
| Total oocytes, median | 14 | 13 | .30 |
| Vitrified metaphase II oocytes,a median | 11 | 12 | .35 |
| Two-pronuclear zygotes,b median | 7.0 | 7.0 | .58 |
| Vitrified blastocysts,b median | 3.0 | 4.0 | .63 |
| Blast utilization rate,b median | 57% | 58% | .74 |
| Cycles with fresh embryo transfersb | 5.1% | 4.2% | .33 |
Note: COS = controlled ovarian stimulation, COVID-19 = coronavirus disease 2019, FSH = follicle-stimulating hormone, PCR = polymerase chain reaction.
a
Oocyte cryopreservation cycles only.
b
In vitro fertilization or embryo banking cycles only.
c
Different laboratory platforms used to evaluate these samples before and during COVID-19.